Physician profile
Robert C Espy
NPI 1205130499
$4,011.29
in general payments reported to CMS, 2019-2025
37 companies · $794 in 2025
The $794 reported for 2025 was more than what 84% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,002 · 2022: $1,122 · 2023: $475 · 2024: $618 · 2025: $794.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,888.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,887.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $486.96 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $368.86 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $323.27 | 2021-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $304.22 | 2021-2024 | Xarelto, Spravato |
| Novo Nordisk INC | $298.82 | 2021-2024 | Ozempic |
| Nevro Corp. | $197.29 | 2021-2023 | Senza |
| Lilly USA, LLC | $191.20 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $183.20 | 2022-2025 | |
| Glaxosmithkline, LLC. | $173.77 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $165.03 | 2022-2025 | Evenity, Repatha, Repatha |
| Otsuka America Pharmaceutical, INC. | $130.27 | 2023-2025 | Rexulti, Nuedexta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $118.24 | 2021-2025 | Ofev, Jardiance |
| Abbott Laboratories | $109.50 | 2021-2023 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $106.58 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $101.12 | 2021-2022 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Espy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.